Eli Lilly has doubled its investment in its new Concord manufacturing facility from $1 billion to $2 billion since construction began in 2022, the company confirmed. The pharmaceutical giant hosted a ...

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. SAN DIEGO — Riding high on the success of its blockbuster weight loss drug, Eli ...

Eli Lilly is releasing new Phase 3 trial results Tuesday. Drugmaker Eli Lilly says its daily oral GLP-1 pill may help people who have obesity and people with Type 2 diabetes lose approximately 23 ...

Eli Lilly is poised to leapfrog Novo Nordisk and become the dominant player in an anti-obesity drug market that could reach ...

Eli Lilly's obesity drugs delivered 38% revenue growth in the second quarter; but its oral GLP-1 candidate fell short, achieving only 12.4% weight loss. Viking Therapeutics' dual-formulation obesity ...

Eli Lilly on Tuesday announced a $5 billion investment in a manufacturing facility in Virginia as the pharmaceutical giant looks to expand its domestic production capacity amid the threat of tariffs.

The three announced Saturday, Aug. 9 the launch of “The Court Is Hers,” an initiative aimed at increasing girls’ participation in basketball by eliminating registration fees for girls basketball ...

HOUSTON — It's official: Big Pharma is landing in Houston. Eli Lilly and Co. (NYSE: LLY) confirmed Sept. 23 that the Bayou City will be part of its domestic manufacturing push. David Ricks, Lilly's ...

Novo Nordisk, the maker of weight loss drug Wegovy, will lay off about 9,000 people as it grapples with rising competition in the obesity market. The Danish company has been battling it out with US ...